Adverse effects of bisphosphonates

Calcified Tissue International

Volumn 86, Issue 6, 2010, Pages 421-435

  Abrahamsen, Bo ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Bisphosphonate; Bone turnover; Exercise; Mechanical loading; Osteoporosis; Remodeling

Indexed keywords

ALENDRONIC ACID; AMINOTRANSFERASE; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIPYRETIC ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; COMPACTIN; DENOSUMAB; ETIDRONIC ACID; GLUCOCORTICOID; HORMONE; IBANDRONIC ACID; MEVINOLIN; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY TUBULE NECROSIS; ACUTE PHASE RESPONSE; ADVERSE DRUG REACTION; ARTHRALGIA; BILIARY CIRRHOSIS; BODY MASS; BONE MINERALIZATION; BONE PAIN; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGUS CANCER; EXHAUSTION; EYE TOXICITY; FATIGUE; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; INTRAVASCULAR HEMOLYSIS; JAW OSTEONECROSIS; LIVER TOXICITY; LOADING DRUG DOSE; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MYALGIA; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERISCLERITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SCLERITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; STOMACH EROSION; STOMACH ULCER; SYNOVITIS; TASTE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; UVEITIS;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 77953190774     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9364-1     Document Type: Review

References (130)

1. NB Watts ST Harris 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis N Engl J Med 323 73 79 1:STN:280: DyaK3c3psVyluw%3D%3D 2113611
2. T Storm G Thamsborg T Steiniche HK Genant OH Sørensen 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis N Engl J Med 322 1265 1272 1:STN:280:DyaK3c3itVOrtg%3D%3D 2109197
3. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs J Dequeker M Favus 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333 1437 1443 1:CAS:528:DyaK28XkslehtA%3D%3D 7477143
4. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D 8950879
5. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082 1:CAS:528:DyaK1MXjsVWruw%3D%3D 9875874
6. B Abrahamsen P Vestergaard 2009 Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006 Osteoporos Int 21 373 380 19436931
7. PC Waller SJ Evans K Beard 2006 Drug safety and the media Br J Clin Pharmacol 61 123 126 16433866
8. RG Russell NB Watts FH Ebetino MJ Rogers 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 733 759 1:CAS:528:DC%2BD1cXltFyjurw%3D 18214569
9. GH Nancollas R Tang RJ Phipps Z Henneman S Gulde W Wu A Mangood RG Russell FH Ebetino 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 617 627 1:CAS:528:DC%2BD28XjvFSjtr4%3D 16046206
10. MA Lawson Z Xia BL Barnett JT Triffitt RJ Phipps JE Dunford RM Locklin FH Ebetino RG Russell 2009 Differences between bisphosphonates in binding affinities for hydroxyapatite J Biomed Mater Res B Appl Biomater 92B 149 155
11. Y Arrain T Masud 2009 Bisphosphonates and osteonecrosis of the jaw-current thoughts Dent Update 36 415 419 19810397
12. AN Tosteson MR Grove CS Hammond MM Moncur GT Ray GM Hebert AR Pressman B Ettinger 2003 Early discontinuation of treatment for osteoporosis Am J Med 115 209 216 12947959
13. DY Graham 2002 What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates Dig Dis Sci 47 1665 1678 1:CAS:528:DC%2BD38Xlt1GnsL8%3D 12184516
14. B Ettinger A Pressman J Schein J Chan P Silver N Connolly 1998 Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation J Manag Care Pharm 4 488 492
15. DY Graham HM Malaty 1999 Alendronate gastric ulcers Aliment Pharmacol Ther 13 515 519 1:STN:280:DyaK1M3jsVCnsw%3D%3D 10215737
16. FL Lanza RH Hunt AB Thomson JM Provenza MA Blank 2000 Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women Gastroenterology 119 631 638 1:CAS:528:DC%2BD3cXmslSku7Y%3D 10982755
17. AB Thomson JK Marshall RH Hunt JM Provenza FL Lanza MG Royer Z Li MA Blank 2002 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status J Rheumatol 29 1965 1974 1:CAS:528:DC%2BD38Xns1aksbs%3D 12233894
18. CJ Rosen MC Hochberg SL Bonnick M McClung P Miller S Broy R Kagan E Chen RA Petruschke DE Thompson AE de Papp 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151 1:CAS:528:DC%2BD2MXptValtA%3D%3D 15619680
19. SM Cadarette JN Katz MA Brookhart T Sturmer MR Stedman R Levin DH Solomon 2009 Comparative gastrointestinal safety of weekly oral bisphosphonates Osteoporos Int 20 1735 1747 1:CAS:528:DC%2BD1MXhtVygt7zO 19266138
20. DK Wysowski 2009 Reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 89 90 1:CAS:528:DC%2BD1MXitVShug%3D%3D 19118315
21. B Abrahamsen P Eiken R Eastell 2009 More on reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 1789 1:CAS:528: DC%2BD1MXkvVygtbw%3D 19387022
22. DH Solomon A Patrick MA Brookhart 2009 More on reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 1790
23. P Vestergaard K Schwartz EM Pinholt L Rejnmark L Mosekilde 2010 Gastric and esophagus events before and during treatment of osteoporosis Calcif Tissue Int 86 110 115 1:CAS:528:DC%2BC3cXovValug%3D%3D 19957165
24. CP Peter LK Handt SM Smith 1998 Esophageal irritation due to alendronate sodium tablets: possible mechanisms Dig Dis Sci 43 1998 2002 1:CAS:528:DyaK1cXmsV2rsr8%3D 9753265
25. AA Reszka J Halasy-Nagy GA Rodan 2001 Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation Mol Pharmacol 59 193 202 1:CAS:528:DC%2BD3MXnsl2isg%3D%3D 11160853
26. LM Lichtenberger JJ Romero GW Gibson MA Blank 2000 Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa Dig Dis Sci 45 1792 1801 1:CAS:528:DC%2BD3cXnvV2ls7o%3D 11052322
27. YX Yang JD Lewis S Epstein DC Metz 2006 Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 296 2947 2953 1:CAS:528:DC%2BD2sXnvVGn 17190895
28. F De Vries AL Cooper SM Cockle TP van Staa C Cooper 2009 Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates Osteoporos Int 20 1989 1998 1:CAS:528:DC%2BD1MXhsVWlsrzM 19333676
29. D Thiebaud A Sauty P Burckhardt P Leuenberger L Sitzler JR Green A Kandra J Zieschang dP Ibarra 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates Calcif Tissue Int 61 386 392 1:CAS:528:DyaK2sXntlCisr8%3D 9351880
30. G Dicuonzo B Vincenzi D Santini G Avvisati L Rocci F Battistoni M Gavasci D Borzomati R Coppola G Tonini 2003 Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 J Interferon Cytokine Res 23 649 654 1:CAS:528:DC%2BD3sXptVyru74%3D 14651779
31. K Thompson MJ Rogers 2004 Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro J Bone Miner Res 19 278 288 1:CAS:528:DC%2BD2cXhs1elsr0%3D 14969398
32. O Bock H Boerst FE Thomasius C Degner M Stephan-Oelkers SM Valentine D Felsenberg 2007 Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention J Musculoskelet Neuronal Interact 7 144 148 1:CAS:528:DC%2BD2sXhtVWnsrbO 17627083
33. DK Wysowski JT Chang 2005 Alendronate and risedronate: reports of severe bone, joint, and muscle pain Arch Intern Med 165 346 347 15710802
34. HJ Demonaco 2009 Patient- and physician-oriented Web sites and drug surveillance: bisphosphonates and severe bone, joint, and muscle pain Arch Intern Med 169 1164 1166 19546419
35. DP Gwynne Jones RL Savage J Highton 2008 Alendronate-induced synovitis J Rheumatol 35 537 538 18203307
36. K Ing-Lorenzini J Desmeules O Plachta D Suva P Dayer R Peter 2009 Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital Drug Saf 32 775 785 1:CAS:528:DC%2BD1MXht1WhsbjL 19670917
37. BA Lenart AS Neviaser S Lyman CC Chang F Edobor-Osula B Steele MC van der Meulen DG Lorich JM Lane 2009 Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study Osteoporos Int 20 1353 1362 1:CAS:528:DC%2BD1MXotlyhurY%3D 19066707
38. B Abrahamsen P Eiken R Eastell 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study J Bone Miner Res 24 1095 1102 1:CAS:528:DC%2BD1MXmvFyjtrY%3D 19113931
39. AS Neviaser JM Lane BA Lenart F Edobor-Osula DG Lorich 2008 Low-energy femoral shaft fractures associated with alendronate use J Orthop Trauma 22 346 350 18448990
40. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155
41. J Schilcher P Aspenberg 2009 Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate Acta Orthop 80 413 415 19568963
42. G Boivin D Farlay Y Bala A Doublier PJ Meunier PD Delmas 2009 Influence of remodeling on the mineralization of bone tissue Osteoporos Int 20 1023 1026 1:STN:280:DC%2BD1MzjtFagtA%3D%3D 19340504
43. MR Allen S Reinwald DB Burr 2008 Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment Calcif Tissue Int 82 354 360 1:CAS:528: DC%2BD1cXnsVCmsb8%3D 18463913
44. RS Weinstein 2000 True strength J Bone Miner Res 15 621 625 1:CAS:528:DC%2BD3cXisFWmtr8%3D 10780853
45. DJ Leeming K Henriksen I Byrjalsen P Qvist SH Madsen P Garnero MA Karsdal 2009 Is bone quality associated with collagen age? Osteoporos Int 20 1461 1470 1:CAS:528:DC%2BD1MXhtVSit7rI 19330423
46. JS Nyman A Roy JH Tyler RL Acuna HJ Gayle X Wang 2007 Age-related factors affecting the postyield energy dissipation of human cortical bone J Orthop Res 25 646 655 17266142
47. MR Allen E Gineyts DJ Leeming DB Burr PD Delmas 2008 Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra Osteoporos Int 19 329 337 1:CAS:528:DC%2BD1cXhtlOqsLk%3D 18094911
48. M Visekruna D Wilson FE McKiernan 2008 Severely suppressed bone turnover and atypical skeletal fragility J Clin Endocrinol Metab 93 2948 2952 1:CAS:528:DC%2BD1cXpvVOmurg%3D 18522980
49. MP Whyte 2009 Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia J Bone Miner Res 24 1132 1134 19113923
50. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301 1:CAS:528:DC%2BD2MXisVOhsr0%3D 15598694
51. Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker RD (2009) Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf). PMID:19302584
52. RK Cheung KK Leung KC Lee TC Chow 2007 Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate Hong Kong Med J 13 485 489 18057440
53. MP Somford FW Draijer BJ Thomassen PM Chavassieux G Boivin SE Papapoulos 2009 Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility J Bone Miner Res 24 1736 1740 19419297
54. DB Burr CH Turner P Naick MR Forwood W Ambrosius MS Hasan R Pidaparti 1998 Does microdamage accumulation affect the mechanical properties of bone? J Biomech 31 337 345 1:STN:280:DyaK1czjsFyjug%3D%3D 9672087
55. DR Carter WC Hayes 1977 Compact bone fatigue damage-I. Residual strength and stiffness J Biomech 10 325 337 1:STN:280:DyaE2s3kvFKqtA%3D%3D 893471
56. MR Allen DB Burr 2008 Skeletal microdamage: less about biomechanics and more about remodeling Clin Rev Bone Miner Metab 6 24 30
57. JG Garrison CL Slaboch GL Niebur 2009 Density and architecture have greater effects on the toughness of trabecular bone than damage Bone 44 924 929 19442628
58. T Mashiba CH Turner T Hirano MR Forwood CC Johnston DB Burr 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone 28 524 531 1:CAS:528:DC%2BD3MXjtlChsLk%3D 11344052
59. ES Siris JA Simon IP Barton MR McClung A Grauer 2008 Effects of risedronate on fracture risk in postmenopausal women with osteopenia Osteoporos Int 19 681 686 1:CAS:528:DC%2BD1cXktV2jtbw%3D 17968610
60. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg RF Gagel V Gilsanz T Guise S Koka LK McCauley J McGowan MD McKee S Mohla DG Pendrys LG Raisz SL Ruggiero DM Shafer L Shum SL Silverman CH Van Poznak N Watts SB Woo E Shane 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 1491 17663640
61. Y Morag M Morag-Hezroni DA Jamadar BB Ward JA Jacobson SR Zwetchkenbaum J Helman 2009 Bisphosphonate-related osteonecrosis of the jaw: a pictorial review Radiographics 29 1971 1984 19926757
62. Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2009) Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig. PMID:19536569
63. DB Burr MR Allen 2009 Mandibular necrosis in beagle dogs treated with bisphosphonates Orthod Craniofac Res 12 221 228 1:STN:280:DC%2BD1Mrht1Cgug%3D%3D 19627524
64. AC Don-Wauchope DE Cole 2009 The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw Clin Biochem 42 1194 1196 1:CAS:528:DC%2BD1MXnt1emtrg%3D 19265689
65. MR Allen 2009 Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench Cells Tissues Organs 189 289 294 1:CAS:528: DC%2BD1cXhsVOgsb3F 18698128
66. K Amagase S Hayashi K Nishikawa E Aihara K Takeuchi 2007 Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats Dig Dis Sci 52 1879 1889 1:CAS:528:DC%2BD2sXntVOlurY%3D 17410434
67. JB Aragon-Ching YM Ning CC Chen L Latham JP Guadagnini JL Gulley PM Arlen JJ Wright H Parnes WD Figg WL Dahut 2009 Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents Cancer Invest 27 221 226 1:CAS:528:DC%2BD1MXktFKitbg%3D 19235596
68. PP Sedghizadeh SK Kumar A Gorur C Schaudinn CF Shuler JW Costerton 2008 Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy J Oral Maxillofac Surg 66 767 775 18355603
69. AO Hoff BB Toth K Altundag MM Johnson CL Warneke M Hu A Nooka G Sayegh V Guarneri K Desrouleaux J Cui A Adamus RF Gagel GN Hortobagyi 2008 Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 826 836 1:CAS:528:DC%2BD1cXnvVGjs70%3D 18558816
70. T Boonyapakorn I Schirmer PA Reichart I Sturm G Massenkeil 2008 Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies Oral Oncol 44 857 869 1:CAS:528:DC%2BD1cXhtVKju7rN 18282788
71. K Vahtsevanos A Kyrgidis E Verrou E Katodritou S Triaridis CG Andreadis I Boukovinas GE Koloutsos Z Teleioudis K Kitikidou P Paraskevopoulos K Zervas K Antoniades 2009 Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 5356 5362 1:CAS:528:DC%2BD1MXhsFKkt7rF 19805682
72. TI Jung F Hoffmann G Glaeske D Felsenberg 2010 Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy J Cancer Res Clin Oncol 136 363 370 1:CAS:528:DC%2BC3cXpsFarsw%3D%3D 19701651
73. JC Lo FS O'Ryan NP Gordon J Yang RL Hui D Martin M Hutchinson PV Lathon G Sanchez P Silver M Chandra CA McCloskey JA Staffa M Willy JV Selby AS Go 2010 Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure J Oral Maxillofac Surg 68 243 253 19772941
74. T Mavrokokki A Cheng B Stein A Goss 2007 Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 65 415 423 17307586
75. PP Sedghizadeh K Stanley M Caligiuri S Hofkes B Lowry CF Shuler 2009 Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry J Am Dent Assoc 140 61 66 19119168
76. VM Cartsos S Zhu AI Zavras 2008 Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people J Am Dent Assoc 139 23 30 18167381
77. M Pazianas WA Blumentals PD Miller 2008 Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker Osteoporos Int 19 773 779 1:CAS:528:DC%2BD1cXltFyjtbo%3D 17999023
78. RE Marx JE Cillo Jr JJ Ulloa 2007 Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2397 2410 18022461
79. R Kunchur A Need T Hughes A Goss 2009 Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws J Oral Maxillofac Surg 67 1167 1173 19446200
80. S Baim PD Miller 2009 Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw J Bone Miner Res 24 561 574 1:CAS:528:DC%2BD1MXksF2lu7k%3D 19257812
81. SA Khan JA Kanis S Vasikaran WF Kline BK Matuszewski EV McCloskey MN Beneton BJ Gertz DG Sciberras SD Holland J Orgee GM Coombes SR Rogers AG Porras 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis J Bone Miner Res 12 1700 1707 1:CAS:528: DyaK2sXmvVSqsbs%3D 9333131
82. SL Ruggiero TB Dodson LA Assael R Landesberg RE Marx B Mehrotra 2009 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update J Oral Maxillofac Surg 67 2 12 19371809
83. PA Price AM Roublick MK Williamson 2006 Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate Kidney Int 70 1577 1583 1:CAS:528:DC%2BD28XhtV2gsrrK 16955099
84. T Delibasi R Emral MF Erdogan N Kamel 2007 Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis Adv Ther 24 319 325 1:CAS:528:DC%2BD2sXot1eisbw%3D 17565922
85. R Ylitalo J Kalliovalkama X Wu H Kankaanranta JP Salenius T Sisto T Lahteenmaki P Ylitalo I Porsti 1998 Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro Pharmacol Toxicol 83 125 131 1:CAS:528:DyaK1cXmt1Sju7Y%3D 9783331
86. M Shimshi E Abe EA Fisher M Zaidi JT Fallon 2005 Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice Biochem Biophys Res Commun 328 790 793 1:CAS:528:DC%2BD2MXhtVKht70%3D 15694415
87. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 17476007 (Pubitemid 46698462)
88. SR Cummings AV Schwartz DM Black 2007 Alendronate and atrial fibrillation N Engl J Med 356 1895 1896 1:CAS:528:DC%2BD2sXltVaisb0%3D 17476024
89. R Karam J Camm M McClung 2007 Yearly zoledronic acid in postmenopausal osteoporosis N Engl J Med 357 712 713 1:CAS:528:DC%2BD2sXptFKqtrY%3D 17703529
90. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 1:CAS:528:DC%2BD2sXht1Kit7nN 17878149
91. SR Heckbert G Li SR Cummings NL Smith BM Psaty 2008 Use of alendronate and risk of incident atrial fibrillation in women Arch Intern Med 168 826 831 1:CAS:528:DC%2BD1cXmtFSrsLk%3D 18443257
92. HT Sorensen S Christensen F Mehnert L Pedersen RD Chapurlat SR Cummings JA Baron 2008 Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study BMJ 336 813 816 18334527
93. B Abrahamsen P Eiken K Brixen 2009 Atrial fibrillation in fracture patients treated with oral bisphosphonates J Intern Med 265 581 592 1:CAS:528:DC%2BD1MXlvFOit7Y%3D 19141097
94. AM From JA Hyder AM Kearns KR Bailey PA Pellikka 2007 Relationship between low bone mineral density and exercise-induced myocardial ischemia Mayo Clin Proc 82 679 685 17550747
95. AE Courtney AP Maxwell 2009 Chronic kidney disease and bisphosphonate treatment: are prescribing guidelines unnecessarily restrictive? Postgrad Med J 85 327 330 1:CAS:528:DC%2BD1MXovFejs7c%3D 19528309
96. ND Toussaint GJ Elder PG Kerr 2009 Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue Clin J Am Soc Nephrol 4 221 233 1:CAS:528:DC%2BD1MXitVWnu78%3D 18987295
97. U Troehler JP Bonjour H Fleisch 1985 Renal transport of bisphosphonates: accumulation by renal cortical slices enhanced by calcium phosphate ions J Lab Clin Med 106 23 29 1:CAS:528:DyaL2MXltlCgtbo%3D 3925057
98. JT Chang L Green J Beitz 2003 Renal failure with the use of zoledronic acid N Engl J Med 349 1676 1679 1:CAS:528:DC%2BD3sXosFakurw%3D 14573746
99. GS Markowitz GB Appel PL Fine AZ Fenves NR Loon S Jagannath JA Kuhn AD Dratch VD D'Agati 2001 Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate J Am Soc Nephrol 12 1164 1172 1:CAS:528:DC%2BD3MXktlyjsLg%3D 11373339
100. GS Markowitz PL Fine VD D'Agati 2002 Nephrotic syndrome after treatment with pamidronate Am J Kidney Dis 39 1118 1122 11979358
101. GS Markowitz PL Fine JI Stack CL Kunis J Radhakrishnan W Palecki J Park SH Nasr S Hoh DS Siegel VD D'Agati 2003 Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 281 289 1:CAS:528: DC%2BD3sXlsFeks74%3D 12787420
102. MA Perazella GS Markowitz 2008 Bisphosphonate nephrotoxicity Kidney Int 74 1385 1393 1:CAS:528:DC%2BD1cXhtlOjtrrJ 18685574
103. J Pascual J Torrealba J Myers S Tome M Samaniego A Musat A Djamali 2007 Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate Osteoporos Int 18 1435 1438 1:STN:280:DC%2BD2srjtVSluw%3D%3D 17404782
104. PD Miller C Roux S Boonen IP Barton LE Dunlap DE Burgio 2005 Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials J Bone Miner Res 20 2105 2115 1:CAS:528:DC%2BD2MXhtlWntrbN 16294264
105. PD Miller 2005 Treatment of osteoporosis in chronic kidney disease and end-stage renal disease Curr Osteoporos Rep 3 5 12 16036095
106. DY Mitchell JV St Peter RA Eusebio KA Pallone SC Kelly DA Russell JD Nesbitt GA Thompson JH Powell 2000 Effect of renal function on risedronate pharmacokinetics after a single oral dose Br J Clin Pharmacol 49 215 222 1:CAS:528:DC%2BD3cXis1ehu74%3D 10718776
107. DD French CE Margo 2008 Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort Retina 28 889 893 18536608
108. S Leung BH Ashar RG Miller 2005 Bisphosphonate-associated scleritis: a case report and review South Med J 98 733 735 16108245
109. FW Fraunfelder FT Fraunfelder B Jensvold 2003 Scleritis and other ocular side effects associated with pamidronate disodium Am J Ophthalmol 135 219 222 1:CAS:528:DC%2BD3sXptFKmtQ%3D%3D 12566027
110. JC Richards SJ Wiffen 2006 Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy Cornea 25 1100 1101 1:STN:280:DC%2BD28jlt1ajtw%3D%3D 17133063
111. ES Siris 1993 Bisphosphonates and iritis Lancet 341 436 437 1:STN:280:DyaK3s7ls1Ggsg%3D%3D 8094197
112. P Musette ML Brandi P Cacoub JM Kaufman R Rizzoli JY Reginster 2010 Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity Osteoporos Int 21 723 732 1:CAS:528: DC%2BC3cXjvFSjtr8%3D 19921087
113. E Phillips S Knowles E Weber NH Shear 1998 Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management J Allergy Clin Immunol 102 697 698 1:CAS:528:DyaK1cXntlWltrg%3D 9802383
114. BA Barrera L Wilton S Harris SA Shakir 2005 Prescription-event monitoring study on 13, 164 patients prescribed risedronate in primary care in England Osteoporos Int 16 1989 1998 16133643
115. PN Biswas LV Wilton SA Shakir 2003 Pharmacovigilance study of alendronate in England Osteoporos Int 14 507 514 1:CAS:528:DC%2BD3sXlt1altrY%3D 12730757
116. AS Kazmi BM Wall 2007 Reversible congestive heart failure related to profound hypocalcemia secondary to hypoparathyroidism Am J Med Sci 333 226 229 17435416
117. AS Kashyap S Kashyap 2000 Hypoparathyroidism unmasked by alendronate Postgrad Med J 76 417 418 1:STN:280:DC%2BD3cvit1CltQ%3D%3D 10878202
118. RJ Maclsaac E Seeman G Jerums 2002 Seizures after alendronate J R Soc Med 95 615 616 12461152
119. SE Meek K Nix 2007 Hypocalcemia after alendronate therapy in a patient with celiac disease Endocr Pract 13 403 407 17669718
120. HE Whitson B Lobaugh KW Lyles 2006 Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone Bone 39 954 958 1:CAS:528:DC%2BD28XpsVOgsr0%3D 16769264
121. M Zuradelli G Masci G Biancofiore G Gullo M Scorsetti P Navarria F Tancioni M Berlusconi L Giordano A Santoro 2009 High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid Oncologist 14 548 556 1:CAS:528:DC%2BD1MXnvVOltr0%3D 19411682
122. B Yanik C Turkay H Atalar 2007 Hepatotoxicity induced by alendronate therapy Osteoporos Int 18 829 831 1:STN:280:DC%2BD2szmvF2lsQ%3D%3D 17226065
123. A Halabe BM Lifschitz J Azuri 2000 Liver damage due to alendronate N Engl J Med 343 365 366 1:STN:280:DC%2BD3czmt1ymtw%3D%3D 10928896
124. R Armamento-Villareal N Napoli V Panwar D Novack 2006 Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis N Engl J Med 355 2048 2050 1:CAS:528:DC%2BD28XhtFymurbI 17093260
125. P Lee WH van der MJ Seibel 2007 Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy J Endocrinol Invest 30 590 597 1:CAS:528:DC%2BD2sXht1yktrzF 17848842
126. EB Kwek SK Goh JS Koh MA Png TS Howe 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39 224 231 18222447
127. AS Sayed-Noor GO Sjoden 2009 Case reports: two femoral insufficiency fractures after long-term alendronate therapy Clin Orthop Relat Res 467 1921 1926 19198962
128. Goddard MS, Reid KR, Johnston JC, Khanuja HS (2009) Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 32:pii. doi: 10.3928/01477447-20090624-27
129. MH Edwards FC McCrae SA Young-Min 2010 Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 21 701 703 1:STN:280:DC%2BC3c7ls1ynuw%3D%3D 19562241
130. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs Jr J Dequeker M Favus 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443 1:CAS:528:DyaK28XkslehtA%3D%3D 7477143